Sanctuary Advisors LLC Reduces Stake in Syndax Pharmaceuticals, Inc.

On March 4th, 2025, it was reported that Sanctuary Advisors LLC has reduced its investment in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 18.6% during the fourth quarter. Following the sale of 5,750 shares, the institutional investor now holds 25,178 shares of the company. The value of Sanctuary Advisors LLC's investment in Syndax Pharmaceuticals was approximately $358,000 at the close of the most recent quarter.

Several other institutional investors have also made changes to their positions in Syndax Pharmaceuticals recently. For instance, the State of New Jersey Common Pension Fund D increased its holdings by 40.5% during the fourth quarter and now owns 133,111 shares valued at $1,760,000 after acquiring 38,339 additional shares. Moreover, abrdn plc bought a new stake in Syndax Pharmaceuticals worth about $1,313,000 during the same period. Additionally, China Universal Asset Management Co. Ltd. raised its stake by 10.6% and now possesses 18,099 shares valued at $239,000 after purchasing 1,732 extra shares. R Squared Ltd. also entered the market by acquiring a new stake valued at about $26,000, while KBC Group NV significantly increased its stake by 104.8%, owning 6,954 shares worth $92,000 after adding 3,559 shares.

Syndax Pharmaceuticals Trading Update

As of Tuesday, SNDX shares began trading at $15.48. Syndax Pharmaceuticals has a market capitalization of $1.32 billion along with a P/E ratio of -4.26 and a beta of 0.90. Over the past year, the stock has reached a low point of $12.06 and a peak of $25.16. The company's 50-day simple moving average stands at $14.23, while the 200-day simple moving average is $16.75.

On March 3rd, Syndax Pharmaceuticals reported its quarterly earnings, indicating a loss of $1.10 per share, which was significantly below analysts' expectations of a loss of $0.31 per share. Analysts project that the company will achieve earnings of -$3.72 per share for the current fiscal year.

Insider Transactions

In related news, CEO Michael A. Metzger sold 13,288 shares on February 10th at an average price of $15.50, resulting in a total value of approximately $205,964. Following this transaction, Metzger currently holds 300,121 shares valued at about $4,651,875.50, marking a 4.24% decrease in ownership. Additionally, CFO Keith A. Goldan sold 3,777 shares on the same day, generating a total of $58,543.50. After this sale, Goldan now owns 90,746 shares valued at approximately $1,406,563, which represents a 4.00% decrease in ownership as well. Over the past ninety days, insiders have sold a total of 21,683 shares worth $336,087, with company insiders currently holding 4.10% of the stock.

Analyst Recommendations

Analysts have varying opinions regarding Syndax Pharmaceuticals' stock. JPMorgan Chase & Co. recently raised their price target for the shares from $33.00 to $38.00, rating the stock as "overweight". Conversely, StockNews.com downgraded the stock from a "hold" rating to a "sell" rating. Scotiabank lowered its target price from $18.00 to $16.00 while assigning a "sector perform" rating. Meanwhile, HC Wainwright maintained a "buy" rating with a target price of $51.00. Citigroup also increased their price target from $37.00 to $45.00, rating the company as a "buy." Among analysts, one has issued a sell rating, one has a hold rating, and nine have given the stock a buy rating, leading to an average rating of "Moderate Buy" and a consensus price target of $36.20 according to MarketBeat.com.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapies for cancer treatment. Its leading products include revumenib, a selective small-molecule inhibitor targeting the menin-MLL binding interaction, specifically for treating KMT2A rearranged acute leukemias and solid tumors. Another significant candidate is SNDX-6352 (axatilimab), a monoclonal antibody designed to block the CSF-1 receptor for treating chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).

SNDX, stocks, investments